Actinogen Medical (ASX: ACW)

Last close As at 29/02/2024


0.00 (3.13%)

Market capitalisation


Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

The unmet need in chronic neurocognitive disorders is tremendous due to the limited effectiveness of available treatment options. The Phase IIb portion of the XanaMIA trial will be key for validating the encouraging Xanamem data shown to date. The XanaCIDD study may also validate the drug’s potential for treating CI related to major depressive disorder.

Latest Insights

View More

Healthcare | Update

Actinogen Medical — Pressing forward with Xanamem

Healthcare | edison tv

Actinogen Medical – executive interview

Actinogen Medical



Equity Analyst

Pooya Hemami

Analyst - Healthcare

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh


Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Balance Sheet

Forecast net debt (A$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 13.8 37.5 (58.6)
Relative 13.1 26.1 (61.2)
52 week high/low A$0.1/A$0.0


Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated with mild-to-moderate Alzheimer’s disease (AD). The study will assess c 220 biomarker-positive AD patients, with interim results expected in H1 CY25. Actinogen recently reported results from a human positron emission tomography (PET) imaging study, which affirm the drug’s mechanism of action (MoA) in healthy subjects and patients with AD, by showing that Xanamem exhibited high target enzyme occupancy designed to impede cortisol production, as well as favourable safety and tolerability. Our risk-adjusted net present value (rNPV) remains essentially unchanged at A$528m.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 3.6 (9.1) (7.9) (0.460) N/A N/A
2023A 4.9 (10.6) (8.9) (0.494) N/A N/A
2024E 7.7 (16.5) (15.8) (0.763) N/A N/A
2025E 20.3 (35.2) (37.9) (1.628) N/A N/A


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free